Citations

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.

NF-κB activating protein (NKAP) plays important roles in various cancers, including breast cancer. However, its expression and prognosis value in breast cancer remains uncertain. Gene expression profiling interactive analysis, Human protein atlas database, and University of Alabama at Birmingham Cancer data analysis portal database were used to predict the expression and prognostic value of NKAP in breast cancer. Immunohistochemistry, quantitative real time polymerase chain reaction (qRT-PCR) and western blot were performed to detect NKAP expression. The effects of NKAP on cell proliferation, migration and drug sensitivity were investigated in MDA-MB-231 and SK-BR-3 cells. NKAP protein expression differed in breast cancer tissues and paraneoplastic tissues based on the cancer genome atlas data. The high NKAP expression was significantly correlated with a poor prognosis in breast cancer patients. The results of immunohistochemistry, western blot assay, and qRT-PCR proved that NKAP was highly expressed in breast cancer tissues compared with paraneoplastic tissues. In addition, qRT-PCR results showed that high expression of NKAP was significantly correlated with the larger tumor size and higher TNM stage. Moreover, knockdown of NKAP significantly inhibited the proliferation, migration, and enhanced drug sensitivity of MDA-MB-231 and SK-BR-3 cells. NKAP is highly expressed in breast cancer tissues, and its high expression is closely associated with poor prognosis. NKAP also promotes proliferation, migration, and inhibits drug sensitivity of breast cancer cells.

Abstract Repetitive injury is hypothesized to lead to progressive tissue fibrosis and end-stage organ failure. Whether tissue-resident mesenchymal cell populations retain epigenetic memory of prior injuries that contribute to this pathological process is unknown. Here we used a genetic lineage labeling approach to mark the lung mesenchyme prior to injury, then performed multimodal analyses on isolated lung mesenchyme during the initiation, progression, and resolution of the fibrotic response. Our results demonstrate the remarkable epigenetic and transcriptional plasticity of the lung mesenchyme during fibrotic activation and de-activation. Despite this plasticity, we also find that the lung mesenchyme exhibits an enhanced fibrotic program upon reinjury. We identify RUNX1 as a critical driver of both fibrotic activation and fibrotic memory. Comparison of fresh isolated and cultured lung mesenchyme demonstrates that RUNX1 is spontaneously activated in standard culture conditions, previously masking these roles of RUNX1. Targeted knockdown of RUNX1 dampens fibrotic mesenchymal cell activation immediately after cell isolation, but with reduced efficacy after only days of culture, confirming its functional importance to both early activation and long-term memory. Collectively, our findings implicate RUNX1 in the initiation and memory of fibrotic mesenchymal cell activation that together prime enhanced mesenchymal cell responses upon repeated injury.

Purpose: While acquired apraxia of speech (AOS) has been the focus of intervention research for decades, little information is reported about the demographic representation of study participants. This article examines the extent to which published AOS treatment studies report participants' age, sex/gender, race/ethnicity, language background, and socioeconomic status; identifies critical gaps in the literature; and considers implications for representativeness. This information supports the important call to capture these patient factors systematically and thereby advance equity in research and clinical care. Method: This study is part of a larger systematic review examining treatment outcomes for acquired AOS. A comprehensive search of databases from 1951 to April 2024 was completed to determine the proportion of treatment articles that reported demographic information related to diversity. Studies were reviewed by trained raters using a standardized data extraction protocol with a consensus protocol. Results: While participant age and sex/gender were reported in nearly all studies (99% and 100%, respectively), only 24% of studies reported on race/ethnicity, 15% provided information on participants' language background, and none reported socioeconomic status. Among studies that included race/ethnicity, 89% of the participants were White, with minimal representation of other racial/ethnic groups. Conclusions: The underreporting of race/ethnicity, language background, and socioeconomic factors limits the generalizability and ecological validity of AOS treatment research. The field must prioritize inclusive participant recruitment and consistent demographic reporting. We propose a practical template for use in both research and clinical contexts to support more thorough data collection and to inform future work in diagnosis, assessment, and intervention for AOS. Supplemental Material: https://doi.org/10.23641/asha.31172353

Abstract Purpose Clinician educators are essential to the academic medicine workforce, yet understanding how they assess their own teaching competencies is limited. The Clinical Educator Milestones (CEMs) guide growth across key educator domains, but their use and perceived relevance remain underexplored. This study aims to (1) evaluate clinician educators’ self-reported performance on the CEMs; (2) examine differences by career level, specialty, and experience; and (3) inform faculty development efforts through a clearer understanding of educators’ perceived strengths and gaps. Method Clinician educators from 9 US academic institutions completed a self-assessment rating their performance across 4 universal pillars and 11 educational theory and practice competencies on a 1- (novice) to 5- (expert) point scale in 0.5-point increments from August to November 2024. Descriptive statistics and mean difference tests were used to analyze variation across demographic and professional characteristics. Results A total of 484 responses to at least 1 CEM were received. Respondents rated themselves highest in commitment to professional responsibilities (mean [SD], 4.30 [0.68]), teaching and facilitating learning (mean [SD], 3.96 [0.74]), and professionalism (mean [SD], 3.93 [0.73]) and lowest in medical education scholarship (mean [SD], 3.11 [1.15]), program evaluation (mean [SD], 3.33 [1.03]), and the science of learning (mean [SD], 3.43 [1.10]). Statistically significant group differences were found by years of posttraining clinical experience (F2,413 = 16.87, P < .001, η2 = .076), years of teaching experience (F2,433 = 20.87, P < .001, η2 = .088), and academic rank (F2,403 = 13.96, P < .001, η2 = .065). Conclusions This study identifies key trends in self-perceived strengths and needs among clinician educators and highlights the limited awareness of the CEM framework. As institutions aim to build effective educator development systems, the CEMs can serve as a useful structure for tailoring support to individuals and identifying institutional needs.

INTRODUCTION: Reliable biomarkers for the diagnosis of chronic pancreatitis (CP) and pancreatic fibrosis severity are lacking, hindering effective treatment and management. Histologic fibrosis is a hallmark of late-stage CP, but noninvasive methods to evaluate fibrosis progression are limited. We used urine proteomics to discover biomarkers that identify patients with CP and predict fibrosis severity. METHODS: We performed a cross-sectional study of 130 total subjects (CP n = 50) selected based on clinical criteria in a tertiary care setting. Urine proteomics samples were quantified using data-independent acquisition mass spectrometry. Differential biomarker candidates were identified with false discovery rate-corrected pairwise comparisons. These proteins were validated with an independent paired urine and plasma sample cohort (n = 36). Machine learning was used to develop a protein panel that predicted Ammann scores for patients with histologic fibrosis. RESULTS: We found 34 proteins consistently differentially expressed between CP and controls in pairwise false discovery rate-controlled tests. Of these, 25 urine proteins outperformed 19 previously suggested CP blood-based biomarkers in an independent validation cohort. Isocitrate dehydrogenase (IDH1), calcyphosin (CAPS), synuclein gamma (SNCG), and protein S100-P (S100P) all produced receiver operator curve area under the curve values >0.95, while the best plasma marker was interleukin 2 receptor subunit alpha (receiver operator curve area under the curve = 0.80). A 12-protein panel of identified markers predicted fibrosis severity with a linear correlation R 2 value of 0.61. DISCUSSION: We identified a panel of proteins that may diagnose CP in children and developed a model to predict pancreatic fibrosis severity, offering promising tools for improving diagnostics and patient care.

The purpose of this study was to examine the validity of a Garmin device for estimating heart rate, energy expenditure, and step count during incremental treadmill exercise. Eighteen physically active males (n = 12; mean ± SD age = 22.8 ± 4.7 years; body mass = 83.8 ± 13.4 kg) and females (n = 6; 24.2 ± 5.6 years; 65.2 ± 9.6 kg) completed an incremental treadmill test with the Garmin Vivoactive 4 and criterion methods measuring heart rate, energy expenditure, and step count. Mean absolute percent error (MAPE) and Bland–Altman plots were used to assess accuracy. Acceptable accuracy was defined as MAPE < 5% for heart rate and <10% for energy expenditure and step count. MAPE (±SD) values were 13.0 (±10.1), 19.1 (±15.0), and 4.6 (±5.3)% for heart rate, energy expenditure, and step count, respectively. The Bland–Altman regression analyses illustrated proportional bias was present for heart rate (r = 0.591, p < 0.001) and step count (r = 0.516, p = 0.028), but not energy expenditure (r = 0.351, p = 0.153). These findings indicated that the Garmin Vivoactive 4 provided acceptable accuracy for step count but unacceptable accuracy for heart rate and energy expenditure during incremental treadmill exercise.

Abstract Cancer occurs in ∼1 per 1000 pregnancies; thousands of patients may require radiation procedures for diagnosis and treatment each year in the United States alone. This rare but high-risk scenario, coupled with fear of radiation, has created ambiguity in the ideal management of pregnant patients. Without a comprehensive guide for the use of radiation in imaging and treatment for pregnant cancer patients, it is difficult for providers to offer optimal patient-centered care without introducing disparities. The goal of this paper is to provide guidance on the use of radiation for screening, diagnosis, staging, and treatment of cancer, while highlighting gaps in existing knowledge and guidelines. The intention is that physicians, medical physicists, and patients could use this document as a resource for shared decision-making, ensuring safe and effective practice. A team of physicians and medical physicists with expertise in imaging, radiotherapy, and maternal fetal medicine was assembled, along with a patient advocate and lawyer. Existing guidelines and recent literature were reviewed. Authors also drew from their experience where published guidance was lacking. The resulting document discusses best practice to guide use of radiation for cancer, as well as patient-centered care management and legal considerations. Overall, it is possible to safely and effectively deliver radiation to pregnant patients in numerous circumstances. Use of radiation or other modalities should be discussed through shared decision-making with the physician and patient, contextualizing the maternal and fetal risk from treatments. Healthcare providers should support wide access to reproductive healthcare to allow equitable, evidence-based, patient-centered healthcare.

Variability and persistent gaps in reporting have been consistently observed across studies evaluating adverse events in healthcare, dating back to the early days of the patient safety movement. Incomplete descriptions—particularly missing details regarding study design, conduct, methodologies and applied definitions—impede interpretation, hinder critical appraisal and limit reproducibility. These deficiencies not only obstruct a shared understanding of findings but also diminish the overall impact such studies may have on patient safety initiatives and policy development. To address these challenges and enhance the quality of reporting, we developed the SESAME (Standard Elements in Studies of Adverse Events and Medical Error) reporting guideline. SESAME is a 44-item checklist designed to support comprehensive and standardised reporting in studies evaluating potential patient harm. The guideline was developed over a 2-year period by an international, multidisciplinary panel through a consensus-driven process aligned with Enhancing the QUAlity and Transparency Of Health Research Network standards.

ABSTRACT Rationale Before evidence‐based practice (EBP) was formally adopted, healthcare decisions relied on critical thinking and clinical judgment informed by disciplinary knowledge, theory, and research, but lacked full integration of patient values with clinical expertise. Sackett et al. redefined EBP as the integration of the best available evidence, clinical expertise, and patient values. This framework has been embraced by nursing and other healthcare disciplines, embedding EBP into education, clinical protocols, and quality improvement efforts. Despite widespread adoption, traditional conceptualizations prioritize empirical evidence above patient values, potentially undermining individualized care. Aims and Objectives This paper proposes a reconceptualization that places patient and client values—their why —at the center of EBP, inspired by Simon Sinek's Golden Circle model which emphasizes starting with purpose to influence behavior effectively. Prioritizing the patient's values before incorporating empirical evidence into a care plan ensures that care aligns with their personal goals and definitions of health, fostering therapeutic relationships and supporting meaningful behavior change. Methods A conceptual analysis was conducted using Simon Sinek's Golden Circle model as a guiding framework. This model emphasizes starting with purpose to influence behavior effectively. The analysis explores how integrating patient values first, followed by empirical evidence and clinical expertise, can operationalize person‐centered EBP. Results The reconceptualized framework positions patient values as the foundation of care planning. By aligning interventions with patients' personal goals and values first, clinicians can strengthen therapeutic relationships and support individualized care. Conclusion Effective nursing clinicians and leaders must embrace this patient‐first approach to truly operationalize person‐centered, evidence‐based care that respects the diverse needs and motivations of patients.